BACE1-AS

Across TCGA pan-cancer cohorts, BACE1-AS RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of BACE1-AS’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where BACE1-AS RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BACE1-AS is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

LIHC, UCEC, and BRCA are the cancer types where BACE1-AS tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BACE1-AS RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.617	<.001	9	view →
UCEC	All	II,III,IV	−0.804	<.001	6	view →
BRCA	Female	All	−0.506	<.001	6	view →
KIRC	All	All	+0.244	.001	6	view →
CHOL	All	All	+2.201	<.001	5	view →
STAD	Male	IV	+1.355	.013	4	view →
BLCA	Male	IV	−1.092	<.001	3	view →
LUAD	Female	All	−0.371	.030	2	view →
LUSC	All	All	−0.302	.004	2	view →
PRAD	All	All	+0.219	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

BACE1-AS–LIHC

Open the LIHC breakdown →